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Inflammatory osteolysis: a conspiracy against bone
Gabriel Mbalaviele,1 Deborah V. Novack,1,2 Georg Schett,3 and Steven L. Teitelbaum1,2
Department of Medicine, Division of Bone and Mineral Diseases, and 2Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine,

1

St. Louis, Missouri, USA. 3Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.

There are many causes of inflammatory osteolysis, but regardless of etiology and cellular contexts, the osteoclast is the
bone-degrading cell. Thus, the impact of inflammatory cytokines on osteoclast formation and function was among the most
important discoveries advancing the treatment of focal osteolysis, leading to development of therapeutic agents that either
directly block the bone-resorptive cell or do so indirectly via cytokine arrest. Despite these advances, a substantial number
of patients with inflammatory arthritis remain resistant to current therapies, and even effective anti-inflammatory drugs
frequently do not repair damaged bone. Thus, insights into events such as those impacted by inflammasomes, which signal
through cytokine-dependent and -independent mechanisms, are needed to optimize treatment of inflammatory osteolysis.

Introduction

The skeleton is a dynamic organ that normally maintains its mass
by collateral osteoblast activity despite constant removal of effete
bone by osteoclasts. Commonly, in states of hormonal deficiency
and aging, this balance is compromised as resorption supersedes
formation, resulting in global loss of bone. Fortuitously, available
and effective osteoporotic therapies are able to enhance systemic
bone mass and reduce fracture risk in aging individuals and postmenopausal women.
Inflammatory diseases that affect joints, skin and the gut —
including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and
Crohn’s disease — also promote bone loss that is often severe
(1–3). Inflammation-driven bone degradation affects the axial and
appendicular skeleton early in life and enhances the risk of fracture. Even when not profound, inflammation increases fracture
risk, underscoring its skeletal relevance (4, 5).
When inflammation occurs in the vicinity of bone, such as in
RA, PsA, orthopedic implant–associated osteolysis, and osteomyelitis, it induces focal erosion that is often devastating. Although
major medical achievements have improved the treatment of
inflammatory arthritides, limitations remain, such as resistance to
therapy in more than one third of RA and PsA patients and failure
to restore damaged bone (6). Thus, further understanding of the
pathogenesis of various forms of focal osteolysis is necessary to
provide a foundation for their prevention and cure.
Immune cells and their products influence the activities of
osteoclasts, osteoblasts, and osteocytes to dictate bone mass and
strength. This relationship of the immune and skeletal systems was
suggested more than 40 years ago by the discovery that stimulated
monocytes produce a catabolic, bone resorption–promoting factor
that was subsequently proven to be IL-1β (7, 8). These observations
and others, including the discovery of the key osteoclastogenic cytokine, RANKL (9), prompted the discipline of osteoimmunology.
In consequence, studies of the means by which cytokines such as
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TNF-α, IL-1β, and IL-17 impact bone cells have provided insights into
the mechanisms of the osteolysis of RA and PsA and improved the
success of cytokine-inhibiting biological drugs in reducing the crippling peri-articular complications of these diseases. Osteoimmunology has also revealed that postmenopausal osteoporosis reflects an
interplay between estrogen deficiency and immune activation (10).
Given the excellent reviews on these topics, we will not address the
role of inflammation in the pathogenesis of systemic bone loss (11).

Osteoclasts are the principal effectors
of inflammatory osteolysis

While resident mesenchymal and immune cells participate in
inflammatory bone destruction, the effector cell of focal osteolysis is the osteoclast, the product of myeloid/macrophage precursor fusion (12). In physiological conditions, osteoclast formation
is dictated by the interaction of RANKL, a member of the TNF
superfamily, with its receptor RANK (9). Interestingly, whereas
high-dose RANKL is potently osteoclastogenic, low-dose RANKL
may actually increase bone formation (13).
RANK activation by RANKL depends upon cytokine-mediated
trimerization of the receptor in a TNF receptor–associated factor 6–dependent (TRAF6-dependent) manner (14–16). RANKL/
RANK signaling induces MAP kinases and NF-κB, eventuating in
the activation and expression of NFATc1, the key osteoclastogenic
transcription factor (17–20). Elevation of RANKL abundance,
which is typically the crucial event regulating bone resorption, is
negatively regulated by osteoprotegerin (OPG) (21–23), a decoy
receptor with a higher affinity for the osteoclastogenic cytokine
than that of RANK; thus, RANKL binding to OPG effectively limits osteoclastogenesis (9, 15). In fact, loss-of-function OPG mutations prompt a severe generalized osteolytic disorder known as
juvenile Paget’s disease (24). Macrophage colony-stimulating factor (M-CSF) is also essential for osteoclast formation, exerting its
effects by signaling via its receptor, C-FMS (25).
The magnitude of bone degradation depends upon both the number of osteoclasts and their individual resorptive capacity. As stated
above, physiological osteoclast abundance is dictated principally
by RANKL, M-CSF, and OPG, which are modulated by cytokines
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Figure 1. Cytokines are key regulators of inflammatory osteolysis. Despite differences in the
pathogenesis of various inflammatory diseases,
proximal regulators of osteoclastogenesis are the
same, although the “cocktail” of these factors
may differ. These factors may act at one or more
aspects of the osteoclastogenic pathway from
osteoclast generation to activation of resorption.
While the homeostatic actions of pro-osteoclast
factors (green) are balanced by those that are
anti-osteoclast (red), pro-osteoclast factors
dominate in inflammatory conditions, thereby
increasing osteoclast number and enhancing the
cell’s capacity to resorb bone. Some factors, such
as IFN-γ, have context-dependent effects on
osteoclasts (see text). HSC, hematopoietic stem
cell; OC, osteoclast.

in states of inflammatory bone disease. Whereas RANKL increases
osteoclast number by promoting precursor differentiation, M-CSF
does so by enhancing proliferation of progenitors and restricting
apoptosis. The capacity of the individual osteoclast to resorb bone,
on the other hand, is largely a product of cytoskeletal organization.
The resorptive machinery polarizes toward the cell-bone interface,
enabling its transport into an isolated resorptive microenvironment
in which degradation of the mineralized and organic components of
the skeleton occurs sequentially (26). This process involves fusion of
cytoplasmic vesicles containing matrix-degrading molecules to the
bone-apposed plasma membrane. Fusion of these lysosome-derived
vesicles to the plasma membrane generates the ruffled border, the
unique resorptive organelle of the osteoclast, which transports mineral-mobilizing HCl and organic matrix–degrading cathepsin K into
the resorptive space (27–31). Polarization of resorptive molecule–
containing vesicles is initiated by signals derived from mineralized
matrix via cell surface integrins, particularly αvβ3 (32). In addition
to their role in osteoclast formation, both RANKL and M-CSF profoundly enhance bone resorption by the mature osteoclast via
canonical organization of its cytoskeleton (33). Given the abundance
of RANKL and M-CSF in states of inflammatory osteolysis, it is likely
that the robust bone destruction reflects both increased numbers
of osteoclasts and enhanced resorptive capacity of the mature cell.
Thus, understanding the means by which inflammation destroys
bone must be viewed in the context of interplay between cytokines
that regulate these two critical osteoclastogenic factors.

Cytokine-induced focal osteolysis in RA

In many circumstances, osteolysis occurs adjacent to inflammation, such as in arthritic periarticular tissue. The secreted products
of infiltrating immune cells perpetuate the inflammatory response

that recruits osteoclasts, the direct mediators of the osteolytic
component of the disease (Figure 1). Thus, anti-osteolytic strategies include inflammatory cytokine inhibition, such as TNF-α and
IL-6 receptor blockade, both of which indirectly diminish osteoclastogenesis, as well as direct inhibition of osteoclast formation
by agents such as denosumab, a humanized anti-RANKL antibody (34). The fact that NF-κB mediates both inflammation and
osteoclast formation suggests its candidacy as a therapeutic target in inflammatory osteolysis (35–38). While an NF-κB–focused
strategy may be compromised by the broad biological necessity of
the transcriptional complex, systemic administration of peptidesiRNA nanocomplexes targeting NF-κB subunit p65 dramatically suppresses the inflammatory and bone-erosive components of
experimental arthritis without apparent off-target effects (39).
A number of inflammatory cytokines may contribute to the
periarticular bone loss of RA, but the most significant is TNF-α.
Macrophages and T cells express TNF-α in the arthritic synovial tissue as a membrane-residing protein that does not promote
osteoclast formation until it is cleaved to its soluble form (40).
Like RANKL, TNF-α exerts its biological effects by clustering
and trimerizing three monomeric receptors (41). In fact, TNF-α
activates two known receptor complexes, namely TNF receptor
type 1 (TNFR1) and type 2 (TNFR2), and each prompts different
intracellular events. TNFR1, which is principally stimulated by
soluble TNF-α, transmits proinflammatory signals and synergizes
with RANK to promote osteoclastogenesis (42). Signals induced
by TNFR2, which largely recognizes membrane-residing TNF-α,
are pro-immunogenic and anti-inflammatory (43). Thus, TNFR1
is responsible for the crippling effects of RA, PsA, and other forms
of focal osteolysis, such as that complicating orthopedic implantation (44, 45). In fact, there is compelling evidence that complicajci.org   Volume 127   Number 6   June 2017

2031

Downloaded from http://www.jci.org on June 6, 2017. https://doi.org/10.1172/JCI93356

REVIEW

The Journal of Clinical Investigation  

tions of anti–TNF-α therapy substantially reflect a failure to distinguish TNFR1 and TNFR2 (46, 47). Recently developed strategies,
including manipulation of affinities for the two receptors to promote selective binding and thus inhibition of TNFR1 while sparing
TNFR2, may attenuate the problematic properties of TNF-α while
maintaining those that are salutary (48).
TNF-α potently stimulates osteoclast formation, but whether
it does so independently of RANKL is controversial. Administration of TNF-α to RANKL-deficient mice fails to induce meaningful
formation of the bone-resorptive cell (49), but TGF-β may substitute for RANKL in certain circumstances (50). Challenging the
concept that RANKL-independent osteoclast formation may participate in inflammatory bone loss is the finding that Rankl-knockout mice are protected from arthritic bone erosions (51). On the
other hand, deletion of RBP-J, a transcription factor that inhibits
osteoclast formation in the context of inflammation, enables
RANKL-independent, TNF-α–induced, but not physiological,
osteoclastogenesis (52). Similarly, absence of TRAF3 or NF-κB2/
p100 alleviates inhibition of osteoclast formation in the context
of TNF stimulation (53). Furthermore, combined TNF-α and
IL-6 promote osteoclast formation and bone erosions in RANK-
depleted myeloid precursors. Osteoclasts are also present, though
diminished, in arthritic mice with inducible RANK deficiency
(54). It therefore appears that in certain circumstances TNF-α may
promote osteoclast formation in the absence of RANKL, but the
biological significance of this event is yet to be defined. It is also
clear that TNF-α and RANKL are synergistic, and the inflammatory cytokine needs only minimal amounts of RANKL to directly
stimulate macrophages to differentiate into osteoclasts (55, 56).
The osteoclast-inducing properties of relatively low quantities
of TNF-α are largely the product of enhanced RANKL expression by mesenchymal cells, such as those residing in pannus, the
inflamed and hypertrophied synovium of arthritic joints (57). As
TNF-α abundance increases, its osteoclastogenic effects progressively reflect direct stimulation of myeloid precursors, while the
contribution made by increasing RANKL diminishes (55, 57, 58).
Thus, osteolysis accompanying relatively modest elevations of
ambient TNF-α depends upon responsive stromal cells. Alternatively, in states of severe periarticular inflammation, TNF-α may
fully exert its bone-erosive effects by directly promoting differentiation of osteoclast precursors and their expression of RANK
receptor independent of cytokine-responsive stromal cells and T
lymphocytes (57). The capacity of TNF-α to prompt RANK expression and osteoclast formation is dependent upon its induction of
M-CSF by stromal cells (59), which increases osteoclast precursor
abundance (60). Importantly, antibody blockade of the M-CSF
receptor C-FMS completely arrests TNF-α–induced osteolysis,
with minimal effects on macrophage number. C-FMS blockade
also limited local and systemic resorption in two mouse models
of inflammatory arthritis (61). Thus, M-CSF and its receptor are
candidate therapeutic targets in inflammatory osteolysis.
Physiological bone remodeling is characterized by a “coupling” of osteoclast and osteoblast activity, and the same holds
true in pathological conditions such as PsA (45). In contrast, the
robust osteoclastogenesis of RA is accompanied by suppressed
bone formation, and thus its erosive lesions exhibit limited osteoblast activity even in face of therapeutic intervention (62). TNF-α
2032
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potently activates the canonical RelA pathway, which inhibits
osteoblast differentiation, and therefore could contribute to the
uncoupling of RA bone resorption from formation (63). However,
this conclusion is controversial, as others report that NF-κB positively affects osteogenesis (64). Given the central role of Wnt signaling in osteoblast differentiation, the failure of RA focal osteolysis to heal is perhaps more likely due to the osteogenic-suppressive
properties of TNF-α mediated through its induction of dickkopf-1
(DKK-1), a potent inhibitor of Wnt activation (65–67). Interestingly,
in contrast to TNF-α arrest, which suppresses osteoclastogenesis
but does not increase bone formation, blockade of DKK-1 does
both, thus repairing erosive lesions (66).
IL-1β, which is abundant in RA pannus and other inflamed
tissues, induces and partners with TNF-α to promote inflammatory osteolysis (58). In this circumstance, TNF-α enhances the
synthesis of IL-1β by synovial fibroblasts (68) and macrophages.
IL-1β, in turn, stimulates expression of RANKL and RANK as well
as its own receptor. In fact, IL-1β mediates approximately 50%
of TNF-α–induced osteoclastogenesis. The interdependency of
TNF-α, RANKL, and IL-1β lends credence to the concept that combined blockade more effectively prevents inflammatory bone loss
than single cytokine inhibition (69).

Autoantibody-induced focal osteolysis in RA

While molecular effectors of innate immunity have been long recognized as mediators of bone loss, until recently little was known
about the role of B cell–produced immunoglobulins as the key
molecular effectors of adaptive immunity in skeletal degradation. Clinical observations suggested that rheumatoid factor, an
immune complex induced by an IgM autoantibody against the Fc
portion of IgG, and anti-citrullinated protein autoantibodies are
potent risk factors for focal osteolysis in RA. Anti-citrullinated
vimentin antibodies directly stimulate myeloid lineage cells to
produce TNF-α and IL-8, which in turn induce osteoclastogenesis (70, 71). Furthermore, individuals with such antibodies but
no signs of RA develop skeletal abnormalities, indicating a direct
effect on bone (72). Immune complexes such as rheumatoid factors also stimulate osteoclast formation and function by crosslinking Fc receptors and activating SYK (73, 74). Importantly,
anti-citrullinated protein autoantibodies and rheumatoid factors
additively trigger bone loss (75).

IL-17 and focal osteolysis in PsA

In contrast to RA, in which TNF-α predominates, PsA is characterized by robust activation of the IL-23/IL-17 axis (76). IL-17 is
produced by Th17 and innate lymphoid (ILC3) cells exposed to
IL-23. IL-17–expressing T cells infiltrate the skin and the joints
of psoriatic patients and likely drive their clinical manifestations. Th17 cells synthesize IL-17 and express RANKL, both of
which directly induce osteoclast differentiation (77, 78). Additionally, IL-17 potentiates RANKL’s osteoclastogenic capacity
by upregulating RANK on osteoclast precursor cells (79). IL-17
also indirectly promotes bone destruction by inducing synovial
fibroblasts and macrophages, respectively, to express TNF-α,
IL-1, and IL-6 (80, 81). In fact, inducing osteolytic cytokines,
especially TNF-α, in these cells, may be the principal means by
which IL-17 causes arthritic osteolysis. In contrast to IL-17, IL-23,
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the essential inducer of Th17 differentiation, does not directly
promote osteoclast formation. The deleterious effects of IL-17
on bone also reflect suppressed osteogenesis via downregulation
of Wnt and BMP pathways (12, 82).
Approximately 90% of PsA patients develop bone erosions
that correlate with the magnitude of joint destruction, establishing
a pathogenic role of the osteoclast. In contrast to RA, whose bone
destructive complications are exclusively resorptive, PsA is characterized by not only robust bone resorption but also exuberant
osteogenesis, particularly in regions of attachment of ligaments
to bone (entheses), which can eventuate in ankyloses (83). While
RA is exclusively characterized by synovial inflammation, patients
with PsA also develop inflamed entheses that may reflect IL-23
and IL-17 activation. Although inflammation is a prerequisite for
new bone formation at entheseal sites, IL-17 is unlikely the responsible factor, as it suppresses rather than promotes osteogenesis.

and limit bone loss in mice following RANKL injection or ovariectomy (92–94). Whether the osteoclast-suppressive properties of
Tregs or Tcregs are compromised in inflamed joints is unknown.
Understanding the role of Th1 cells in the skeleton has been
more complex than exploring Tregs. Activated Th1 cells were originally considered pro-osteoclastogenic, as they express RANKL
(95). Th1 cells, however, actually suppress osteoclast formation
in vitro, postulated to be via co-production of IFN-γ, challenging
their role in RA-associated focal osteolysis (18, 78). Surprisingly,
however, human CD4+IFN-γ+ T but not CD4+IFN-γ– T cells express
RANKL and thus promote osteoclastogenesis (96). Importantly,
CD4+IFN-γ+ T cells are selectively increased in the circulation of
RA patients and IFN-γ stimulates osteoclast formation and bone
loss in vivo (96, 97). Thus, Th1-produced IFN-γ appears to directly
inhibit and indirectly stimulate osteoclast formation, with the latter predominating in vivo.

Immunoregulatory mechanisms inhibiting focal
arthritic osteolysis

Skeletal changes associated with excessive
inflammasome activation

Macrophages are central to the pathogenesis of focal osteolysis, as
they are a principal source of inflammatory cytokines and can differentiate into osteoclasts. In fact, the abundance of macrophages
in pannus parallels disease severity (84). While the osteoclast is a
macrophage lineage cell, its precise origin remains controversial
and it is likely influenced by specific environmental circumstances. This is particularly true regarding the relationship of osteoclasts
to classically activated, proinflammatory M1 and alternatively
activated, immunoregulatory M2 macrophages. Assumption of
the M2 phenotype typically requires IL-4 and IL-13, which inhibit
osteoclast formation and induce myeloid progenitors to develop
into non-bone-resorbing polykaryons (85). IL-4 and IL-13 are the
products of Th2 lymphocytes and eosinophils, respectively. These
cells suppress inflammatory arthritis and hence its osteolytic consequences (86). TNF-α, which promotes osteoclast formation,
blunts polarization to the M2 phenotype directly and by arresting production of IL-13 by eosinophils that are present in arthritic
joints (86, 87). While these observations suggest that osteoclasts
are not derived from alternatively activated M2 macrophages,
inflammatory arthritis in mice recruits osteoclast precursors with
features of both M1 and M2 cells (88). Hence, differentiation of a
monocytic precursor into osteoclasts may essentially depend on
the cytokine micro-milieu to which the cell is exposed, thus allowing a modicum of plasticity in monocyte differentiation.
In addition to stimulating resorption, immune cells may
retard osteoclast formation and bone loss. For example, CD4+
FoxP3+ Tregs are potent inhibitors of osteoclast differentiation,
exerting their effects by cell contact (89). The anti-resorptive
capacity of Tregs reflects their anti-inflammatory properties. They
also directly block osteoclast formation by liganding CD80/CD80
surface receptors with CTLA4, thereby inducing indoleamine
2,3-deoxygenase (IDO) (90). In inflammatory conditions, however, the immune-suppressive capacity of Tregs is compromised by
proinflammatory cytokines, which promote targeted dephosphorylation of FoxP3 (91). A second population of Tregs that express
CD8, known as Tcregs, is directly induced via interaction with
osteoclasts (92). These Tcregs inhibit the resorptive activity of
osteoclasts, rather than inhibiting their differentiation in vitro,

Inflammasomes are intracellular protein complexes expressed
mainly by myeloid cells, including osteoclasts (98, 99), but also
develop in osteoblasts and chondrocytes (98, 100, 101). They protect against infections upon recognition of microbial structures
known as pathogen-associated molecular patterns (PAMPs) (102).
Inflammasomes also restore tissue integrity after injury by sensing
danger-associated molecular patterns (DAMPs) from damaged
cells (103–105). They function primarily by converting pro–IL-1β
and pro–IL-18 to their biologically active forms (103).
Inflammasomes are assembled by nucleotide-binding oligomerization domain, leucine-rich repeat–containing proteins
(NLRP1, NLRP3, NLRC4, NLRP6, and NLRP12), absent in melanoma 2–like (AIM 2-like) receptors (known as ALRs), or pyrin (ref.
103 and Figure 2). These proteins act as receptors for PAMP- and
DAMP-associated molecular patterns. Ligand recognition enables
the recruitment and oligomerization of apoptosis-associated
speck-like protein containing a caspase activation recruitment
domain (CARD). Complex assembly activates caspase 1, which
proteolytically processes pro–IL-1β and pro–IL-18. The NLRP3
inflammasome signaling cascade cleaves poly(ADP-ribose) polymerase 1 (PARP1) (106–108).
Owing to its robust activation by monosodium urate crystals,
the NLRP3 inflammasome plays a key role in gout (109). The
NLRP3 inflammasome is also activated in RA synovium, consistent with increased IL-1β secretion (110, 111). TNF-α stimulates
IL-1β expression in vitro, suggesting the latter cytokine may drive
pro–IL-1β transcription in RA. Although TNF-α and IL-1β regulate
each other’s expression and osteoclastogenic properties (58), the
superior efficacy of TNF-α inhibitors in RA relative to those that
block IL-1 is consistent with the apical role of TNF-α in generating
focal osteolysis in this disease.
As stated above, inflammasomes also promote cleavage of
PARP1 (106–108). While it has yet to be studied in the context
of RA, PARP1 proteolysis occurs during osteoclastogenesis (98,
99, 112, 113). A proteolytically stable PARP1 mutant antagonizes
osteoclastogenesis, whereas PARP1 deficiency enhances this process (107, 114), indicating that PARP1 negatively regulates osteoclast differentiation.
jci.org   Volume 127   Number 6   June 2017
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Figure 2. The inflammasomes in osteolysis.
Cytokines such as TNF induce the expression
of pro–IL-1β, which lacks the signal peptide for
secretion. Recognition of damage- or pathogen-
associated molecular patterns (DAMPs or
PAMPs) by the receptor/sensor component of
the inflammasome (e.g., NLRP3, NLRC4), or
activating mutations of some of these receptors,
leads to the assembly of the inflammasome, a
protein complex containing the receptor, apoptosis-associated speck-like protein containing
a CARD (ASC) and caspase 1. Once assembled,
this active complex cleaves pro–IL-1β into active
IL-1β and triggers cascades that lead to PARP1
cleavage into p89 and p24 fragments. In precursors sensing DAMPs or PAMPs, cleaved PARP1
and autocrine effects of IL-1β, acting through
IL-1R, promote maturation of osteoclasts into
bone-resorbing cells. Secreted IL-1β can also act
in a paracrine manner to increase bone resorption
by nearby osteoclasts. Dashed arrows indicate
multiple steps.

Inflammasome mutations may prompt stimulus-independent activation and are the cause of cryopyrin-associated periodic syndromes (CAPS). Neonatal-onset multisystem inflammatory disease (NOMID), the most severe CAPS, is attended by
bone loss and skeletal deformation (101, 115–118). IL-1–blocking
agents have limited efficacy against NOMID skeletal lesions,
while other symptoms related to systemic inflammation are rapidly resolved (119–122). While the human disease is phenocopied
in mouse models with global NOMID mutation (98, 123), mice
bearing the mutation only in osteoclasts lack systemic inflammation but have severe osteoporosis (99), indicating a cell-autonomous role in the bone-resorptive cell.
In humans, gain-of-function mutations in NLRC4 cause
a disorder reminiscent of macrophage activation syndrome
(MAS) (124–127), a life-threatening complication of systemic
juvenile idiopathic arthritis (JIA). JIA responds to IL-1 blockers
(128, 129), indicating the inflammasome-activated cytokine
participates in this osteolytic disorder. Consistent with the
human phenotype, transgenic mice expressing constitutively
active NLRC4 develop inflammatory arthritis (130). Similarly,
activating mutations of MEFV, encoding pyrin, cause familial
Mediterranean fever (FMF), which is characterized by excessive IL-1β that drives autoinflammation associated with arthritis and bone loss (131, 132). The efficacy of IL-1 blockers underscores the pathogenic action of this cytokine in FMF (133).
2034
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Additionally, mice harboring mutant MEFV establish that the
pyrin inflammasome is proinflammatory and causes massive
cartilage and bone erosion (134).
Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory osteolytic disorder. Anti-inflammatory cytokines
(e.g., IL-10) are diminished, whereas their proinflammatory counterparts (e.g., IL-1β, IL-6, and TNF-α) are increased. This imbalance presumably reflects NLRP3 inflammasome hyperactivation
and causes exaggerated osteoclastogenesis (135). Immunohistochemical staining of bone of CRMO patients shows that the NLRP3
inflammasome is increased in osteoclasts (136). Supporting the
role of cytokines in bone loss during CRMO, TNF-α or IL-1 blockers are efficacious (135). Mice harboring a spontaneous missense
mutation in the proline-serine-threonine phosphatase-interacting
protein 2 (Pstpip2) gene, which abolishes protein expression, develop a phenotype reminiscent of CRMO, with enhanced osteoclastogenesis and bone resorption (137). These mutant mice overproduce IL-1β due to combined and redundant actions of the NLRP3
inflammasome and caspase 8 (138–140), suggesting that inflammasome-independent IL-1β release may occur in some situations.

Pathogenesis of periprosthetic osteolysis

Periprosthetic osteolysis is the most significant long-term complication of total hip replacement. Prosthetic-wear particles activate
innate immune responses, causing excessive bone resorption and,
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ultimately, implant failure (141, 142). The prevalence of myeloid
cell responses indicates that the NLRP3 inflammasome likely participates in prosthetic loosening, implicating crystalline particles
in the pathogenesis of NLRP3-mediated diseases. Furthermore,
calvarial bone resorption that is induced by polymethylmethacrylate (PMMA) particles is reduced in the absence of NLRP3 (143).
The size and shape of metal alloys affect the amplitude of the
inflammasome response (144). Plastic components of the prostheses also activate the inflammasome. Phagocytosis-enhanced
production of reactive oxygen species and rupture of phagosomes,
which release cathepsins in the cytoplasm, are the presumed
mechanisms of NLRP3 inflammasome activation by particles.
On the other hand, prosthetic particles generate priming signals
through TLRs that induce expression of pro–IL-1β and NLRP3
(145, 146). The NLRP3 inflammasome, however, appears to supersede TLR4 signaling in prosthetic-wear particle-induced osteolysis (147). On the other hand, the non-NLR inflammasome AIM2
and not NLRP3 may mediate the acute phase of PMMA-induced
foreign body responses (148).

Infection-associated osteolysis

Immune activation during infection causes profound local bone
loss. Although the term may refer to any instance of bone inflammation, osteomyelitis (OM) is primarily used to describe the
infection-induced form of disease whose progression is the result
of interplay among pathogens, the cellular and matrix constituents of bone, and the immune system. Bacteria may cause bone
necrosis through direct killing of osteoblasts, but the inflammatory response is likely the major event by which infection induces
osteoclastogenesis and bone degradation. The most frequently
identified microorganism in OM is Staphylococcus aureus, which
is seeded into bone through both hematogenous and direct (e.g.,
trauma, implant) routes in children and adults (149).
Bacterial products of Staphylococcus aureus, which grows primarily in the extracellular bone microenvironment and forms
biofilms, induce an inflammatory response. Factors released by
cells adjacent to bacteria include TNF-α, IL-1β, IL-6, IFN-γ, and
IL-12 as well as the chemokines CCL3 (also known as MIP1α),
CXCL1, CXCL2 (also known as MIP2α), and CXCL8 (150–154).
Further linking mechanisms of bone loss in infectious and
non-infectious inflammatory states, the NLRP3 inflammasome
is implicated in the response of innate immune cells to Staphylococcus aureus infection. Hemolysins, bacterial lipoproteins, and
Panton-Valentine leukocidin from Staphylococcus aureus are all
activators of NLRP3 capable of inducing IL-1β release (155–157).
In addition to the caspase 1–mediated IL-1β processing event,
NLRP3 activation induces expression of a variety of cytokines
in an NF-κB–dependent, caspase 1–independent fashion (158).
As discussed above, although individual inflammasome factors
may inhibit osteoclast formation or function, combined release
is highly osteolytic (151, 159, 160).
In addition to mediating osteolysis via activation of immune
cells, Staphylococcus aureus directly affects osteoblasts. Staphylococcal protein A binds to and activates TNFR1 on osteoblasts,
thereby stimulating NF-κB and promoting IL-6 secretion (161).
The cell wall component peptidoglycan stimulates TLR2 in a
NOD2-dependent manner, thereby inducing RANKL expression

by osteoblasts. Concordant OPG remains unchanged (159, 162,
163) or decreases (164), contributing to osteoclast recruitment
and osteolysis. Bone loss likely also occurs through reduced osteoblast viability as well as reduced activity induced by substances
released from staphylococcal biofilms (163, 164).
Alveolar bone loss due to periodontitis is another frequent
form of infection-mediated inflammatory osteolysis. In this context, the most common pathogen is Porphyromonas gingivalis,
although the human disease is likely polymicrobial, as the oral
cavity is not a sterile site (165). Alveolar bone loss elicited by Porphyromonas gingivalis shares many features of lysis attending OM.
Cytokine release (166) as well as induction of RANKL downstream
of TLR2 and NOD2 are the prominent pathways leading to osteoclast activation in periodontitis (167, 168). IL-17 is also markedly
increased in periodontitis and appears to be an important factor in
both inflammation and osteolysis of the periodontal tissue (169).
Porphyromonas gingivalis also releases cysteine proteases called
gingipains, which do not directly induce osteoclastogenesis (170)
but may act via differential degradation of osteoclast-modulatory
cytokines, including OPG (171).

Therapeutic perspective

In the not-too-distant past, many patients with RA or PsA were incapacitated because of focal osteolysis, which destroyed periarticular
bone. Insights gained into the pathogenesis of inflammatory osteolysis, and in particular the interplay of the immune and skeletal systems, has led to substantial therapeutic progress. RANKL inhibition
by denosumab, for example, arrests progression of arthritic osteolysis, supporting the concept that stimulated osteoclastogenesis is the
essential event in inflammatory bone loss (172). However, RANKL
inhibition, per se, has no intrinsic anti-inflammatory properties and
therefore must be accompanied by anti-inflammatory agents in
these disorders (172). All current cytokine inhibitors approved for
the treatment of inflammatory diseases, which include compounds
specifically targeting IL-1, IL-6R, IL-17, IL-12/23, and in particular
TNF-α, limit osteolysis (173–175). The efficacy of TNF-α inhibitors
appears to reflect combined anti-inflammatory properties and direct
suppression of bone-resorbing osteoclasts. IL-6R inhibitors, which
are used exclusively to treat RA, and IL-12/23 and IL-17 blocking
agents, predominantly employed in psoriatic arthritis, exert similar
bone-protective effects. The impressive skeletal-sparing properties
of IL-1 blockers are surprising, as these drugs minimally diminish
the articular inflammation of RA, supporting the concept that the
cytokine’s primary effect, in the disease, is direct osteoclast recruitment and activation (176). Clinically, IL-1 inhibitors may have their
primary bone-protective role in crystal arthropathies such as gout,
where IL-1β plays a dominant role as an inflammatory cytokine
(177). A small molecule inhibitor of the NLRP3 inflammasome has
shown efficacy in rodent disease models (178), thus providing proof
of concept that pharmacologic inhibition of this inflammasome is a
viable therapeutic strategy. However, there is no report on NLRP3
inhibitors in clinical development. Drugs interfering with adaptive
immune response, particularly T cell activation, also regulate bone
resorption. CTLA4, for instance, which retards T cell activation and
is effective in RA, binds osteoclast precursors and arrests their differentiation (179). The anti-osteoclastogenic properties of Tregs are
mediated by CTLA4, which these cells constitutively express (179).
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Since infection-induced osteolysis is primarily the result of the
host response rather than the direct action of pathogens, blockade
of cytokines and/or RANKL could be a useful adjunct to debridement and antibiotic therapy. RANKL blockade has been successful in animal models of periodontitis (180–182). Patients treated
with anti–TNF-α therapy for other disorders have also shown some
improvement in alveolar bone loss (183).
In summary, while the clinical consequences of skeletal
inflammation have long been appreciated, recent discoveries
of immune pathways controlling bone homeostasis have added
greatly to our understanding as to how these pathological events
occur. Inflammatory cytokines, autoantibodies, and DAMPs/
PAMPs induce osteoclast differentiation and osteolysis in autoinflammatory, autoimmune, and infectious diseases. These discoveries prompted therapeutic interventions, such as cytokine
blockers, which selectively disrupt the detrimental skeletal effects
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